Objectives: Development of a novel drug candidate with improved activity against influenza virus neuraminidase (NA) compared with currently available therapeutics.
Introduction
Influenza is one of the most common respiratory diseases. People of all ages and social backgrounds worldwide regularly suffer from this infection. Increased morbidity is observed annually during global seasonal epidemics. In severe cases, increased mortality is also observed, especially in resource-limited countries with inadequate provision of pharmaceuticals. For example, in the USA, 10% of the population show symptoms of infection each year. More than 220 000 hospitalizations and 24000 deaths due to influenza-associated illnesses are registered each year. 1 The highest hospitalization rate is generally observed among the aged ( 20% of deaths), children and young people. 2 In addition to vaccines, synthetic small molecules are currently considered promising therapies against both viral types A and B. Oseltamivir phosphate 3 (Figure 1 ), originally developed by Gilead Sciences, and zanamivir 4 are the most effective oral neuraminidase (NA) inhibitors, with relatively high antiviral potency.
Oseltamivir phosphate is the prodrug of oseltamivir carboxylate (IC 50 ¼ 0.490+13 nM for NA inhibition in the H1N1, MadinDarby canine kidney epithelial cell plaque assay). 5 With respect to the route of administration, cost of production and structure optimization, the development of novel small molecules targeting influenza is undoubtedly attractive.
Recently, we announced a novel compound [(3R,4R,5S)-4-(2,2-difluoroacetylamino)-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid; AV5027] with picomolar activity against influenza NA. 6 In addition, a detailed quantitative structure -activity relationship (QSAR) study was performed using three-dimensional molecular docking and classical regression analysis. Here, we describe key pharmacokinetic features and the in vitro and in vivo (animal models) activities of AV5027 analogues (AV5075, AV5095, AV5102 and AV5092) (Figure 1 ), mesylates (AV5075S and AV5095S) and metabolites. We found that AV5095 was formed in a neutral solution in human, dog and rat plasma by the acylation of AV5075. 
Materials and methods

Animals
Specific-pathogen-free female white outbred mice (12 -14 g ) were obtained from the nursery 'Andreevka' (Moscow region, Russia). Mice were quarantined for 24 h prior to infection. Specific-pathogen-free CD1 mice (6 weeks of age) and Sprague-Dawley rats (250 -350 g) were obtained from the Laboratory Animal Breeding Branch of the Institute of Bioorganic Chemistry, Russian Academy of Sciences (Moscow region, Russia). Pubescent beagle dogs of both sexes (10 -12 kg) were obtained from the Animal Breeding Facility, Russian Research Center of Biologically Active Substances (Moscow region, Russia). Sprague-Dawley rats were quarantined for 10 days prior to the study of pharmacokinetics. The animals were kept in separate rooms with a controlled microclimate (temperature 18 -268C, relative humidity 30%+70%, 8 -10 volumes of room air per hour and 12 h day/night cycle). Maintenance and care were in accordance with the Guide for the Care and Use of Laboratory Animals. 7 
NA assay
The effect of compounds on NA activity was measured using the WHO protocol. 8 2-(4-Methylumbelliferyl)-a-D-N-acetylneuraminic acid sodium salt (MUNANA; Sigma, cat. no. M8639), at a final concentration of 0.1 mM, was used as the fluorescent substrate. Diluted allantoic virus containing 800-1200 fluorescence units of MUNANA was mixed with the test compound (0.01-10000 nM) in 33 mM 2-(N-morpholino)ethanesulphonic acid (pH¼6.5) containing 4 mM CaCl 2 and incubated for 30 min at 378C. After adding the substrate and incubating at 378C for 1 h, the reaction was stopped by adding 0.14 M NaOH in 83% ethanol. Fluorescence was measured at an excitation wavelength of 360 nm and an emission wavelength of 448 nm. Substrate blanks were subtracted from the sample readings. The IC 50 values were then calculated by plotting the percentage inhibition of NA activity versus the inhibitor concentration. The results were reported as the average of three experiments.
Three-dimensional molecular docking
Molecular docking was performed using ICM-Pro software (official web site: www.molsoft.com) 9 and crystallographic data for proteins isolated from influenza-type viruses that were available in the PDB (official web site: www.rcsb.org). 10 For in silico modelling, we used crystallographic data obtained for H1N1 influenza NA in complex with oseltamivir carboxylate (PDB code: 3TI6). 11 The binding mode for oseltamivir carboxylate was compared with that observed for laninamivir 12 and zanamivir.
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Chemistry
General and analytical chemistry, as well as synthetic protocols, are presented in the Supplementary data (available at JAC Online). Oseltamivir carboxylate and oseltamivir phosphate were prepared as described previously. 6 [(3R,4R,5S)-5-amino-4-(2,2-difluoroacetylamino)-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid] ethyl ester mesylate (AV5075S) was synthesized starting from commercially available (3R,4R,5S)-4-amino-5-buthoxycarbonylaminoamino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid and the corresponding ethyl ester 13, 14 (see Scheme S1, available as Supplementary data at JAC Online). (3R,4R,5S)-4-amino-5-(2,2-difluoroacetamido)-3-(1-ethylpropoxy)cyclohex-1-enecarboxylic acid (AV5102) and its ethyl ester (AV5095) were synthesized from (3R,4R,5S)-ethyl-4-amino-5-azido-3-(1-ethylpropoxy)cyclohex-1-enecarboxylate. 15 AV5095S and AV5102 were prepared as shown in Scheme S2 (available as Supplementary data at JAC Online). Ivachtchenko et al.
In vitro stability of AV5075S, AV5095S and AV5027 in buffers and plasma
In vitro stability of AV5075S, AV5095S and AV5027 was evaluated as described previously. 16 -18 Compounds were incubated in universal buffers (1 mM) at pH¼2, 4 or 7.4 and in human, dog and rat plasma in duplicate at 378C with gentle shaking. Aliquots (60 mL) were collected at predetermined timepoints (0, 1, 4 and 24 h), followed by extraction with acetonitrile (180 mL) containing 50 ng/mL of the internal standard tolbutamide. Samples were incubated at 2208C for 15 min and then centrifuged at 2000 g for 10 min. Supernatants were analysed by LC-MS/MS. Acetonitrile, DMSO, formic acid and water were of HPLC grade (Panreac). Tolbutamide and verapamil were obtained from Sigma. Pooled human plasma in sodium citrate Sprague-Dawley rat plasma and canine plasma (mixed breed) in Na 2 EDTA were obtained from Innovative Research (Novi, MI, USA). Universal buffer was obtained from pION-Inc. (USA) and used at the desired pH.
Pharmacokinetics of AV5075S, AV5095S and AV5092
For pharmacokinetics studies, male Sprague-Dawley rats and male beagle dogs were used (see the Animals section). All experimental procedures and protocols were reviewed and approved by the Animal Care and Use Committee of the Chemical Diversity Research Institute, according to the Guide for the Care and Use of Laboratory Animals. Animals were housed under controlled conditions (22 -268C, relative humidity 30% -70%) with a natural light/dark cycle. They were allowed to adapt to the housing environment for ≥1 week before the study. Animals were fasted for 12 h before the study with free access to water. AV5075S and AV5095S were formulated in 20% hydroxypropylbetacyclodextran for intravenous administration and in 0.5% hydroxypropylmethylcellulose for peroral administration in rats. Compounds were used in a single intravenous (2 mg/kg) or oral (30 mg/kg) dose to previously cannulated male Sprague-Dawley rats (n¼3/dose); all blood samples were taken from the same animal during the study. In dogs, compounds were administered in capsules at 40 mg/kg (n ¼4/dose). 
LC-MS/MS analysis of samples after stability and pharmacokinetic studies
A mass spectrometer (QTRAP 5500; AB Sciex, USA) coupled with a UPLC system (1290 Infinity; Agilent Technologies, Inc., USA) was used with a YMC-Triart C18 column (1.9 mm/12 nm/50×2 mm). Gradient elution was employed (flow rate: 0.4 mL/min) with a mobile phase of water/acetonitrile with 0.1% formic acid. Compounds were ionized in positive electrospray ionization mode. The mass transitions were as follows: for AV5075S and AV5095S, m/z 349.2 120.0; for AV5027, m/z 321.0 251.0; for AV5102, m/z 321.0 138.0; and for AV5092, m/z 243.2 138.0. Internal standard normalized areas under the curve (AUCs) were used to calculate the parent drug remaining at each timepoint in stability studies (relative to t¼0 min in %). Concentrations were determined from standard calibration curves in the range 1 -4000 ng/mL. Pharmacokinetic data were analysed using WinNonlin software (Phoenix Corp., USA) with non-compartmental models. Parameters calculated included the maximal plasma concentration (C max ) and time (T max ), area under the plasma concentration curve from first to last timepoint (AUC 0 -t ) and with linear extrapolation to infinity (AUC 0 -1 ), elimination rate constant (k el ), half-life (t1 2 ), mean residence time, clearance (CL) and volume of distribution (V). Oral bioavailability was calculated based on AUC 0 -t .
Assessment of efficacy in vivo
Female (12 -14 g) specific-pathogen-free white outbred mice were anaesthetized by inhalation of ether diethyl and were challenged intranasally by 4000 pfu (10 MLD 50 , where MLD 50 is the 50% lethal dose for mice) mouse-adapted A/Aichi/2/68 (H3N2) virus in 100 mL of phosphatebuffered saline (PBS). The MLD 50 was calculated after a 16 day observation period for each experiment. Compounds AV5075S, AV5075S, AV5092 and oseltamivir (5, 15, 30 or 50 mg/kg of body weight/day) were administered Novel picomolar neuraminidase inhibitor-AV5075S 1313 JAC 
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1315 JAC by oral gavage twice per day for 6 days (10 -15 mice). The first dose was given 2 h before intranasal inoculation with virus. The second dose was given 6 h after inoculation. Virus-inoculated control mice received sterile PBS (placebo) on the same schedule. Survival and weight change were observed for 16 days until surviving mice started to gain weight. The mice were weighed on days 0 -5 (daily), 7, 9, 11, 13 and 15 days after infection. Loss or gain in weight was calculated for each mouse as a percentage relative to weight on day 0 prior to inoculation. Average values are presented as percentage changes in weight+SEM. The mean survival day (MSD) was calculated by the following equation: MSD¼[f(d21)]/n, where f is the number of survivors on day d (survivors on day 16 were included in f for that day) and n is the number of mice in the group. 19 All studies were approved by the Animal Care and Use Committee of the I. Mechnikov Research Institute of Vaccines and Sera and were conducted in strict accordance with applicable laws and guidelines.
Results
In vitro NA inhibition
Based on the likelihood that the presented compounds (AV5027, AV5102 and AV5092) would inhibit NA given that the lead compound (oseltamivir) is a well-substantiated NA inhibitor, they were tested using the NA assay described above. IC 50 values against A/California/7/2009 (H1N1) viral NA are presented in 
Three-dimensional molecular docking
Molecular docking was performed as described previously. 5 The active site of NA was constructed based on the reported oseltamivir carboxylate binding mode. The model was validated using oseltamivir carboxylate, zanamivir and their direct analogues. The obtained results were compared with related X-ray structures (Figure 2) . The predicted active conformations of the reference compounds correlated well with the available crystallographic data [PDB codes: 3TI5, 3TI4, 3TI3 and 3B7E]. The developed threedimensional model demonstrated high predictive validity and effectively classified compounds by the target activity, at least within the scope of this chemotype. For each compound, ≥10 different conformations were generated in ICM-Pro. All Tentative prognosis based on two score functions (Molsoft score and mfScore).
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conformations from the output were within a particular range around the minimum of the potential energy. For assessment, we used internal 'score' functions calculated automatically in ICM-Pro. Generally, a score of 230 or lower is considered good, depending on the receptor (e.g. exposed pockets or pockets with metal ions may give scores higher than 230). During modelling, we thoroughly analysed all scores that were generated. Of these values, we have selected the best score for the conformation that is most closely related to the template supramolecular interface ( Table 2) .
As shown in Table 2 , low scores generally correspond to high activities and vice versa. For example, for the two template molecules, oseltamivir carboxylate and zanamivir, the in silico scores were 224.24 and 226.56, respectively, while the inhibitory 
Quantity of AV5075+AV5095 is expressed in relative units. ). However, due to significant overlap in SEM, these activities cannot be firmly attributed to the observed scores. In other words, only three values for oseltamivir carboxylate, zanamivir and AV5027 can be treated as statistically significant inputs for QSAR modelling. These insufficient conditions prevent the creation of a computational model with strong predictive ability. Therefore, on the basis of two score functions, an expert prognosis has been given for proposed metabolites M1-M5 (see Table 2 ). It should be noted that M1 showed the lowest in silico score (230.53); the predicted IC 50 for this compound was 0.10 nM. This compound was predicted to be the most active NA inhibitor within the series.
In vitro stability of AV5075S, AV5095S and AV5027 in buffers and plasma
The stability of AV5075S, AV5095S and AV5027 was evaluated in universal buffers with pH ¼ 2, 4 and 7.4 and in human, dog and rat plasma at 378C. LC-MS/MS was used for the analysis of the parent compounds and metabolites after 1, 4 and 24 h of incubation and the stability was calculated as a percentage of the value at t¼0. The results are shown in Tables 3 and 4 . As is clearly shown in Table 3 , after 24 h at physiological pH (7.4), only 36% of AV5075S (AV5075 + AV5095) was converted, giving 6.46% of AV5027 and 1.7% of AV5102. In the case of AV5095S (AV5095 + AV5075), conversion was 50.6%, while 11.78% of AV5027 was formed along with 3.28% of AV5102. In human Ivachtchenko et al.
plasma, the amount of parent compound AV5075S (AV5075 + AV5095) fell to 47.2% after 24 h, while AV5027 and AV5102 rose to 10.45% and 5.1%, respectively.
Pharmacokinetics and bioavailability of AV5075S, AV5095S and AV5092
Pharmacokinetics in rats was investigated after the intravenous or peroral administration of a single dose and in dogs after the peroral administration of AV5075S and AV5095S. LC-MS/MS was used for the analysis of the plasma concentration of parent compounds and metabolites. Pharmacokinetic curves are shown in Tables S1 -S5 (available as Supplementary data at JAC Online).
We investigated the metabolism of these compounds using a typical pharmacokinetic mouse model. Metabolic transformations, similar to that observed for oseltamivir phosphate, 20 -23 were proposed for AV5075S after peroral administration in animals ( Figure 6 ). AV5027 was identified as the main metabolite. Reacetylation of AV5075S was observed, giving AV5095 followed by the formation of metabolite AV5102, particularly during the synthesis of the amino intermediate. Metabolites AV5027 and AV5102 can be further transformed into the N-deacetylated product AV5092. 
Assessment of compound efficacy in vivo
Infected mice (see the LC-MS/MS analysis of samples after stability and pharmacokinetic studies section) were treated with the synthesized compounds. The results of a comprehensive comparative study of these compounds against a lethal dose of A/ Aichi/2/68 (H3N2) virus in mice are presented in Table 5 . Compounds AV5075S, AV5095S, AV5092 and oseltamivir (5, 15, 30 or 50 mg/kg of body weight/day) were administrated in mice (10 -15 mice per group) by oral gavage twice per day. All the tested compounds, as well as oseltamivir carboxylate, were administered 2 h before and 6 h after viral inoculation and then twice per 5 day period. The first dose was given before intranasal inoculation. Virus-inoculated control mice received sterile PBS (placebo) at the same schedule. Survival and weight change were observed for 16 days. Animals that showed signs of severe disease and weight loss of 25% were humanely killed and regarded as having died. A relatively high mortality rate (81% -100%) and loss in body weight (10% -21%) were observed after viral infection. AV5095S was effective against viral infection at all dosages investigated. Administration of AV5095S in doses of 5, 15 or 30 mg/kg/day significantly increased survival rate (80% -91%) and time to death compared with untreated control mice. The most profound therapeutic effect (90% -100% survival) was observed for AV5095S at 50 mg/kg/day. In addition, treatment with AV5095S at all doses studied abolished weight loss ( Figure 7 ). The pairwise comparison of survival rates did not show superiority for either AV5095S or oseltamivir carboxylate in doses starting from 15 mg/kg/day for treating A/Aichi/2/68 infection in mice. Mice receiving AV5095S
(5 mg/kg/day) had a higher survival rate (80%) than those receiving oseltamivir at the same dose (60%). Treatment with AV5095S (5 mg/kg/day) or oseltamivir carboxylate resulted in a mean survival time of 13.9 or 12.4 days, respectively. AV5095S was studied at 50 mg/kg/day and showed a significant therapeutic effect, comparable to oseltamivir carboxylate at the same dose. Administration of AV5095S (5 mg/kg/day) protected 90% of infected mice, significantly delayed the day of death (up to twice the survival time) and prevented weight loss ( Figure 7 ). AV5092 at 50 mg/kg/day was not more effective than AV5075S or AV5095S compared with oseltamivir carboxylate at the same dose under the same conditions. The number of survivors and the survival time was greater in mice treated with AV5092 (50 mg/kg/day) than in untreated mice. Additionally, survivors Three-dimensional molecular docking of AV5027, AV5092, AV5095 and oseltamivir carboxylate revealed similar binding modes for these compounds within the active binding site of NA (H1N1), with some variation around the 4,5-diamino fragment (see Table 2 ). At the same time, the predicted supramolecular interface for metabolites M1 -M5 is slightly different. Thus, the highest score was calculated for metabolite M1 (ICM-Pro score: 230.53), which has an oxidized terminal methyl group (1-ethylpropoxy fragment). For this compound, additional H-bonds ( 2 Å ) are observed between the implicit OH-group and adjusted E276 and N294, with insignificant steric obstructions. It should be noted that the docking scores show excellent correlation with the observed biological activities.
In summary, we evaluated the efficacy of AV5075S, AV5095S and AV5092 at various doses and timepoints (see above) in an influenza A virus model. Because oseltamivir phosphate (Tamiflu) is an approved oral NA inhibitor, we have used this compound as a control. These biological trials revealed AV5075S as a highly effective competitive inhibitor of NA activity in the A/Aichi/ 2/68 model. Administration of AV5075S at doses of 5, 15, 30 or 50 mg/kg/day provided high or total protection from death, significantly delayed death and abolished weight loss compared with untreated mice. The therapeutic efficacy of AV5075S at doses of 15, 30 or 50 mg/kg/day was close to that of oseltamivir at the same oral dose and schedule in terms of survival, survival time and weight loss. However, treatment with AV5075S at 5 mg/ kg/day was superior to oseltamivir phosphate at the same dose. Mice receiving AV5075S (5 mg/kg/day) showed a higher survival rate (up to 80% -90%) and prolonged duration of survival ( 2.7 times longer) than for oseltamivir at the same dose (60% and 2.4 times, respectively). No significant difference was detected in the weight loss data for AV5075S and oseltamivir. AV5075S at 50 mg/kg/day showed a successful therapeutic outcome in animals infected with the virus compared with controls. Presumably, the relatively high efficacy of AV5095S upon peroral administration may be due to its conversion into AV5102, with further isomerization into AV5027 in blood. Under the same experimental conditions, treatment with AV5092 at 50 mg/kg/day provided no significant protection against lethality and no shift was observed in survival time compared with oseltamivir, AV5095S or AV5095S. The weight loss data were consistent with the survival data and indicated that treatment with AV5092 at 50 mg/kg/day was not effective in preventing weight loss.
This study provides a novel highly potent drug candidate, AV5075S, with picomolar activity against influenza virus NA. The stability of this compound was investigated in blood samples as well as animal models. The main metabolic pathway and isomerization points were also studied. This study revealed that AV5027 was the key metabolite, with picomolar activity against NA, in a mouse model. In addition, we observed no toxic effects at the therapeutic dose of AV5075S; therefore, a clinical trial in humans is proposed for this compound, which will be performed during the upcoming year. Figure 8 . Structures of the suggested metabolites of AV5027.
